|
Submitted 10/2009
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients. |
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events!
CFCF Fundraising Events
|
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS From 990
| |
|
|
|
|
|
Breaking News for Carcinoid and NET Patients
 Riad Salem, MD plans to hold a podcast discussing the treatment of neuroendocrine tumors using radiation microspheres.
Stay tuned! On Tuesday, December 8th at 8 pm (EDT), Dr. Salem, an interventional radiologist and director of interventional oncology at Northwestern Memorial Hospital, will be holding an online audio podcast entitled, "Novel Approaches for Patients with Neuroendocrine Tumors Using Radiation Microspheres." Click HERE to access the podcast.
Aaron I. Vinik, MD, PhD, Maria P. Silva, MD, Gene Woltering, MD, Vay Liang W. Go, MD, Richard Warner, MD, and Martyn Caplin, MD authored a review article for the November issue of Pancreas entitled, "Biochemical Testing for Neuroendocrine Tumors."
This new review article discusses the use of biochemical markers for the diagnosis of neuroendocrine tumors and exclusion of conditions that masquerade as neuroendocrine tumors. Please click HERE to view the article abstract and email CFCF by clicking HERE for additional information. |
|
Attention All Carcinoid and NET Patients!
 CFCF encourages all carcinoid and related neuroendocrine tumor patients to join NORD (National Organization of Rare Disorders) in its fight to end lifetime insurance caps as soon as possible.
CFCF understands that many patients must seek out costly therapeutic alternatives in order to receive the best care available. Furthermore, this issue is particularly relevant to patients with carcinoid and related neuroendocrine tumors, who may require chronic care and high-cost drug therapies. Therefore, CFCF supports NORD in rejecting lifetime insurance caps in insurance markets. Here are sample letters that you can personalize for your Senator and Representative. |
|
CFCF in Action
 CFCF applauds its recent marathon team participants who ran the Chicago Marathon and, most recently, the Marine Corps Marathon as well as the generous donors who supported these runners.
Together, the teams have raised approximately $40,000. We are so grateful for these efforts, which are instrumental in helping CFCF launch the FIRST large-scale genome study of carcinoid tumors led by Matthew Meyerson, MD, PhD of Dana-Farber Cancer Institute. In addition, the Steve and Caroline Kaufer Fund for Neuroendocrine Research agreed to match all donations that went toward these events and plans to match additional donations until December 31, 2009. Click HERE to view opportunities to join us for a cure and participate in upcoming CFCF team events. |
|
|
|
|
